KRAS status was determined by whole exome sequencing (WES) of tumor tissue in 301 patients with LUAD of the 1274 randomized participants with NSCLC, being 69/301 (22.9%) KRAS mt LUAD. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.